Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

The panelist discusses how early detection of recurrent Clostridioides difficile infections is critical in clinical practice because these infections can rapidly escalate patient morbidity and ...

Clostridioides difficile (C. diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC). It can worsen symptoms and cause complications. It can also trigger a ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Pfizer's vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a ...

In fecal transplant, bacteria from a healthy person’s gut is transferred into a person with GI problems. The procedure is ...

Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...